Posts found in:
Grantees

Dr. Andrew Inltekofer

Dr. Andrew Inltekofer

Published: Jan 14, 2022   |   Author: Jason Butler   |   No Comments

Title of Grant:       Elucidating and targeting IDH2 mutations in T cell lymphoma  Description: Drugs that target mutant forms of the metabolic enzyme isocitrate dehydrogenase 2 (IDH2) are a promising appraoch to treat some cancers. The proposed research will uncover how mutant IDH2 causes T cell lymphoma and determine whether inhibiting mutant IDH2 offers an effective […]

Read more
Dr. Angieszka Czechowicz

Dr. Angieszka Czechowicz

Published: Jun 9, 2020   |   Author: Jason Butler   |   No Comments

Title of Grant: “Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia (AML)” Acute myeloid leukemia (AML) is a frequent type of leukemia with harsh treatments and poor outcomes. We have pioneered several new antibody therapies targeting an important receptor found both on blood stem cells and AML, […]

Read more
Marco Ruella, MD

Marco Ruella, MD

Published: May 20, 2020   |   Author: Jen Ranieri   |   No Comments

“Increasing the Therapeutic Index of Chimeric Antigen Receptor T cells for T cell Lymphomas” Our goal is to bring the unquestioned power of CAR T cell therapy to bear on T cell lymphomas, a group of diseases with a poor prognosis and few treatment options. We will use the latest gene-editing tools to make an […]

Read more
Dr. Sahand Hormoz

Dr. Sahand Hormoz

Published: May 20, 2020   |   Author: Jen Ranieri   |   No Comments

“Reconstructing the differentiation dynamics and genealogy of cancer cells in individual patients with myeloproliferative neoplasms using single-cell sequencing” In a type of blood cancer called myeloproliferative neoplasm, the same genetic alteration results in drastically different forms of the disease in different patients. To understand this discrepancy, we will measure the molecular profile of individual cells […]

Read more
Dr. Pengda Liu

Dr. Pengda Liu

Published: May 20, 2020   |   Author: Jen Ranieri   |   No Comments

“Targeting the Innate Immunity-Independent Function of STING in treating AML” This proposal is to test if inhibiting a deubiquitinase named OTUD7B retards AML growth. We found that AML growth is controlled by an immunity sensor STING through activating an oncogenic kinase called mTOR. This process is facilitated by OTUD7B. Thus, inhibiting OTUD7B suppresses STING-mediated mTOR […]

Read more
Naama Kanarek, PhD

Naama Kanarek, PhD

Published: May 20, 2020   |   Author: Jen Ranieri   |   No Comments

“A simple dietary supplement to improve pediatric blood cancer therapy” We propose to improve the use of methotrexate – the standard pediatric leukemia drug – with a simple dietary supplement. By enhancing methotrexate’s efficacy, and better monitoring patients’ responses to the drug, we aim to reduce the therapy’s long-term side effects and offer hope to […]

Read more
Jeffrey Bednarski MD, PhD

Jeffrey Bednarski MD, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“B Cell Specific DNA Damage Responses Prevent Leukemic Transformation” Pediatric acute lymphoblastic leukemia occurs as a result of genetic mutations that block normal development of immune cells and promote continued expansion of cancer cells. The goals of Dr. Bednarksi’s project is to understand how cells prevent generation of these mutations and how cells are eliminated […]

Read more
Daniel Herranz Benito, PhD

Daniel Herranz Benito, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“The role of SIRT1 in the pathogenesis and treatment of T-Cell Acute Lymphoblastic Leukemia” T-Cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive blood cancer where 20-50% of patients relapse, and there are few therapeutic options at this stage. Notch1 activating mutations are the main driver in T-ALL. However, responses observed with targeted therapies against NOTCH1 […]

Read more
Ann Mullally, MD

Ann Mullally, MD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Biology and Therapeutic Targeting of Mutant Calreticulin in Myeloproliferative Neoplasms” Somatic mutations in celreticulin (CALR)are frequent and disease-initiating in myeloproliferative neoplasms (MPN). Dr. Mullally’s laboratory recently elucidated the mechanism by which mutant CALR is oncogenic and induces MPN. Building on this work and guided by strong preliminary data they have generated, she will now identify […]

Read more
Richard Possemato, PhD

Richard Possemato, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Modulating Iron Metabolism to Treat Myelodysplastic Syndrome” In Myelodysplastic Syndrome red blood cell formation is impaired, leading to severe progressive anemia. Mutation of SF3B1 often causes Myelodysplastic Syndrome, and is associated with the appearance of iron-loaded immature red blood cells. We propose to use genetic tools to repair this altered iron metabolism, restoring red blood […]

Read more
Esther Obeng, MD

Esther Obeng, MD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Targeting SF3B1 in myelodysplastic syndrome” Myelodysplastic syndromes (MDS) are a group of pre-leukemia blood disorders with a high risk of progression to aggressive leukemia, SF3B1 mutations are frequent, early events in MDS pathogenesis and ideal therapeutic targets. The proposed studies will evaluate how SF3B1 mutations cause MDS and test novel agents in SF3B1-mutant cells.

Read more
Bilal Omer, MD

Bilal Omer, MD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Engineering more potent T cells to target lymphoma associated antigens” We have developed strategies to grow a patient’s own immune cells in the laboratory and then re-inject them into the patient to fight lymphoma. In a clinical trial at our center, 3 of 7 patients with active lymphoma responded to this treatment without the need […]

Read more